CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vistagen Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vistagen Therapeutics Inc
343 Allerton Ave
Phone: (650) 577-3600p:650 577-3600 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: VTGNVTGN
Business Summary
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20253/31/2025YesYes---

Industries
SIC Code Description
5961 Catalog and mail-order houses
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Margaret M.Fitzpatrick 59 10/1/2023 7/1/2021
Chief Executive Officer, Director Shawn K.Singh 60 3/31/2018 5/11/2011
Chief Financial Officer CynthiaAnderson 54 8/21/2023 8/21/2023
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Pherin Pharmaceuticals, Inc. 58 West Portal Ave. San Francisco CA United States

Business Names
Business Name
Origen Therapeutics, Inc.
Pherin Pharmaceuticals, Inc.
VistaGen Therapeutics, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 56 (As of 5/31/2025)
Outstanding Shares: 29,157,733 (As of 6/10/2025)
Shareholders: 357
Stock Exchange: NASD
Federal Tax Id: 205093315


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, June 28, 2025